Cantor Fitzgerald Estimates GH Research FY2026 Earnings

GH Research PLC (NASDAQ:GHRS - Free Report) - Analysts at Cantor Fitzgerald issued their FY2026 earnings per share estimates for GH Research in a report issued on Monday, June 9th. Cantor Fitzgerald analyst C. Duncan forecasts that the company will earn ($1.72) per share for the year. Cantor Fitzgerald currently has a "Overweight" rating and a $25.00 target price on the stock. The consensus estimate for GH Research's current full-year earnings is ($0.80) per share.

A number of other research analysts also recently weighed in on the company. Guggenheim cut their price target on GH Research from $32.00 to $29.00 and set a "buy" rating on the stock in a research note on Friday, May 9th. HC Wainwright reiterated a "buy" rating and issued a $40.00 price objective on shares of GH Research in a report on Friday, May 9th. Wall Street Zen cut GH Research from a "hold" rating to a "sell" rating in a report on Thursday, May 22nd. Royal Bank of Canada assumed coverage on GH Research in a research report on Friday, March 7th. They set an "outperform" rating and a $31.00 target price for the company. Finally, Stifel Nicolaus upped their price target on GH Research from $18.00 to $32.00 and gave the company a "buy" rating in a research note on Thursday, February 27th. One investment analyst has rated the stock with a sell rating and seven have issued a buy rating to the company's stock. Based on data from MarketBeat, GH Research currently has a consensus rating of "Moderate Buy" and an average target price of $32.00.

GH Research Stock Down 0.5%

GHRS stock traded down $0.07 during midday trading on Tuesday, reaching $12.76. The company's stock had a trading volume of 146,854 shares, compared to its average volume of 187,917. The business's 50-day simple moving average is $10.73 and its 200-day simple moving average is $10.38. GH Research has a 52 week low of $6.00 and a 52 week high of $20.50. The stock has a market cap of $663.88 million, a PE ratio of -16.15 and a beta of 0.97.

GH Research (NASDAQ:GHRS - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The company reported ($0.19) EPS for the quarter, topping the consensus estimate of ($0.61) by $0.42.

Hedge Funds Weigh In On GH Research

Institutional investors have recently modified their holdings of the business. Geode Capital Management LLC increased its stake in GH Research by 4.5% during the 4th quarter. Geode Capital Management LLC now owns 72,513 shares of the company's stock worth $508,000 after purchasing an additional 3,092 shares in the last quarter. Diadema Partners LP acquired a new position in shares of GH Research in the fourth quarter valued at approximately $711,000. Lynx1 Capital Management LP boosted its holdings in shares of GH Research by 15.8% in the fourth quarter. Lynx1 Capital Management LP now owns 4,858,994 shares of the company's stock valued at $34,013,000 after buying an additional 663,100 shares during the period. Northern Trust Corp increased its position in shares of GH Research by 26.8% during the fourth quarter. Northern Trust Corp now owns 40,834 shares of the company's stock worth $286,000 after acquiring an additional 8,641 shares in the last quarter. Finally, AdvisorShares Investments LLC increased its position in shares of GH Research by 15.4% during the fourth quarter. AdvisorShares Investments LLC now owns 36,011 shares of the company's stock worth $252,000 after acquiring an additional 4,806 shares in the last quarter. Institutional investors own 56.90% of the company's stock.

About GH Research

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).